Guardant Health reports results from NILE study

Guardant Health announced results from the NILE study, a head-to-head comparison of the Guardant360 assay to standard-of-care tissue testing for the identification of guideline-recommended biomarkers in first-line advanced non-small cell lung cancer, or NSCLC, patients. These data show that Guardant360 detected targetable genomic biomarkers at a similar rate to tissue and support the use of blood-based biomarker testing ahead of tissue-based testing for all newly diagnosed advanced NSCLC patients. Investigators found that Guardant360 identified guideline recommended-biomarkers in 77 patients; tissue testing identified them in 60. Importantly, for each patient in whom Guardant360 identified a target of an FDA-approved drug, tissue also detected the same alteration. Additionally, the median time to results for Guardant360 was much shorter than for tissue testing. Guardant360 results were reported in an average of 9 days, versus 15 days for tissue. The NILE study met its primary endpoint of demonstrating comparable performance of Guardant360 to tissue.
https://thefly.com/landingPageNews.php?id=2871687